The U.K.'s drug and medical technology regulatory body, the MHRA, will continually monitor all artificial intelligence-based devices.
This will be a major step up from the current policy, which relies on one initial check-and-done approach.
As part of this response, the MHRA is also opening the call for applications for the third phase of its so-called “AI Airlock,” its regulatory sandbox for AI-enabled medical devices, with testing informed by the Commission's recommendations.
The reforms aim to ensure patients can benefit from safe, effective and trusted AI more quickly, while maintaining robust safeguards as technologies evolve.”
This comes amid growing trepidation more broadly in some quarters, notably within the AI industry itself, of how quickly AI is developing and how well safeguards are keeping up with the pace of development.
【MORE】